Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

scPharmaceuticals, Inc. (SCPH) had Revenue of $11.75M for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$11.75M
Net Income	$-19.74M
Cost of Goods Sold	$3.47M
Gross Profit	$8.28M
Operating Expenses	$29.51M
Operating Income	$-17.76M
Non-Operating Income/Expense	$-1.99M
Pre-Tax Income	$-19.74M
Normalized Pre-Tax Income	$-19.74M
Income after Taxes	$-19.74M
Income from Continuous Operations	$-19.74M
Consolidated Net Income/Loss	$-19.74M
Normalized Income after Taxes	$-19.74M
EBIT	$-17.76M
EBITDA	$-17.69M
Weighted-Average Shares Outstanding (Basic)	53.68M
Weighted-Average Shares Outstanding (Diluted)	53.68M
Earnings per Share (EPS) (Basic)	$-0.37
Earnings per Share (EPS) (Diluted)	$-0.37
Balance Sheet Financials
Current Assets	$89.35M
Property, Plant, and Equipment	$0.05M
Long-Term Assets	$1.61M
Total Assets	$90.96M
Current Liabilities	$16.31M
Long-Term Debt	$51.05M
Long-Term Liabilities	$79.78M
Total Liabilities	$96.09M
Common Equity	$-5.13M
Tangible Shareholders Equity	$-5.13M
Shareholders Equity	$-5.13M
Common Shares Outstanding	50.28M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-17.14M
Cash Flow from Investing Activities	--
Cash Flow from Financial Activities	$-0.97M
Beginning Cash	$75.66M
End Cash	$57.54M
Increase/Decrease in Cash	$-18.11M
Stock-Based Compensation	$1.29M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	5.48
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	1.11
Debt to Equity Ratio	-9.96
Gross Margin	70.46%
Operating Margin	-151.10%
EBIT Margin	-151.10%
EBITDA Margin	--
Pre-Tax Profit Margin	-167.99%
Profit Margin	-167.99%
Free Cash Flow	$-17.14M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.13
Inventory Turnover	0.25
Receiveable Turnover	0.85
Days Sales in Receivables	106.10
Return on Equity	385.06%
Return on Tangible Equity	385.06%
Return on Assets	-21.70%
Return on Investments	-42.99%
Book Value Per Share	$-0.10
Free Cash Flow per Share	$-0.32
Operating Cash Flow per Share	$-0.32

Data from Zacks Investment Research, Inc.